The food–drug gap
U.S. law sorts a plant product by the claim made for it, not by how long people have used it, and a treatment claim makes it a drug. Few botanicals cross that line because the proof is costly, cannot be owned, and is hard to reproduce batch to batch.
Not legal advice. This page explains published law and data as of October 28, 2026. EUTECNIQ Sciences is a company in formation: no laboratory, products, studies or claims exist, and everything about EUTECNIQ below is proposed.
Start here if new to the topic: Course 10, Supplements and disease claims covers DSHEA, the ten disease-claim criteria of 21 CFR 101.93(g), FTC substantiation and a sorter of FDA's own examples. This page goes one level down: why the gap exists and what can legitimately be done about it.
Intended use sets the category
A drug is any article “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” (FD&C Act § 201(g)(1)(B)). Origin does not enter the test. Psyllium husk shows it: it is sold as a supplement ingredient, it carries an authorized health claim, and it can be sold under an over-the-counter drug monograph, depending on what the label says the product is for. Between “supports normal function” and “treats” there are two rungs, both about reducing disease risk, and each needs more evidence than the one below.
| Rung | May say | What it needs | Botanical example |
|---|---|---|---|
| Structure/function statement | How an ingredient affects the normal structure or function of the body; may not claim to diagnose, mitigate, treat, cure or prevent a disease | Notice to FDA no later than 30 days after first marketing; the label disclaimer “This statement has not been evaluated by the Food and Drug Administration…”; substantiation held by the firm | Any supplement label; FDA does not review the statement before sale |
| Qualified health claim | A relationship between a substance and reduced risk of a disease, with qualifying language on the strength of evidence | Petition; FDA letter of enforcement discretion | Cranberry products and reduced risk of recurrent urinary tract infection in healthy women (letter of July 21, 2020); psyllium husk and type 2 diabetes (June 24, 2014) |
| Authorized health claim | A relationship between a substance and reduced risk of a disease | “Significant scientific agreement, among experts qualified by scientific training and experience” (21 CFR 101.14(c)); an FDA regulation | Psyllium husk and heart disease (21 CFR 101.81): 7 g or more of soluble fiber from psyllium seed husk per day, at least 1.7 g per serving |
| Drug claim | Diagnoses, cures, mitigates, treats or prevents a disease | Clinical investigation under an IND and approval of an NDA or BLA | Four approvals: sinecatechins (Veregen, 2006), crofelemer (Fulyzaq, also Mytesi, 2012), anacaulase-bcdb (NexoBrid, BLA, 2022), birch triterpenes (Filsuvez, 2023) |
Sources: 21 USC 321 and 343 (LII, read October 28, 2026); eCFR 21 CFR 101.14, 101.81, 101.93 (current to October 2026); FDA qualified health claims list; FDA CDER botanical drug page; approval years from Park et al., Ther Innov Regul Sci 2025. Psyllium and witch hazel can also be sold under certain over-the-counter drug monographs (FDA CDER).
Proof that nobody can own
A product of nature is not patent-eligible merely because it was isolated (Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576, 2013), and natural laws are not patentable (Mayo v. Prometheus, 566 U.S. 66, 2012). A firm can patent a composition, a process, a formulation or a method of use, but not the plant or its known constituent. Drugs add statutory exclusivity on top of patents; supplements get none. A trial on a widely sold extract therefore helps every seller of that extract, and the firm that paid for it cannot stop them.
| Protection | Approved botanical drug | Botanical supplement |
|---|---|---|
| Patent on the plant or a known constituent as such | No (Myriad 2013; Mayo 2012) | No |
| Patent on a composition, process, formulation or method of use | Available | Available |
| New chemical entity exclusivity | 5 years, if the active ingredient qualifies | None |
| New clinical investigation exclusivity | 3 years | None |
| Orphan drug exclusivity | 7 years | None |
| Claim the trial earns | The approved indication | At most a health claim on risk reduction; never treatment |
The record shows the result. When the HHS Office of Inspector General collected the substantiation that 66 of 104 manufacturers sent for their structure/function claims, “only 2 percent of the 557 human studies” examined the actual products sampled, and 85 percent were not randomized, double-blind, parallel-group and placebo-controlled.
Sources: 569 U.S. 576 (2013); 566 U.S. 66 (2012); FDA patents and exclusivity FAQ; HHS OIG, Dietary Supplements: Structure/Function Claims Fail To Meet Federal Requirements, OEI-01-11-00210, October 2012, pp. 11–13. Whether a given ingredient qualifies for any exclusivity is a case-specific legal question.
The first-lawful-use race
The supplement definition excludes an article approved as a new drug, or authorized for investigation as one where “substantial clinical investigations have been instituted” and made public, if it “was not before such approval, certification, licensing, or authorization marketed as a dietary supplement or as a food” (21 USC 321(ff)(3)(B)). Order decides the channel. A firm that runs a public drug program first can close the supplement market for that article; a firm that sells first keeps it open for everyone.
| Question in § 201(ff)(3)(B) | FDA's answer for CBD |
|---|---|
| Is it the active ingredient in an approved drug? | Yes: “CBD is the active ingredient in the approved drug product, Epidiolex.” |
| Were substantial clinical investigations instituted and made public? | Yes, FDA states they were |
| Was it marketed as a supplement or food first? | Not the case, based on the evidence available to FDA |
| Can FDA lift the exclusion? | Only by notice-and-comment regulation; FDA states it has issued none for any substance |
Source: FDA cannabis and CBD page (read October 28, 2026). The same page reaches the same conclusion for THC (Marinol, Syndros).
Why botanical drug programs stall
A botanical drug is a mixture whose composition moves with species, cultivar, soil, harvest and extraction. FDA authors reviewing 739 botanical INDs report that standard chemistry, manufacturing and controls “alone sometimes are not sufficient”; early programs were held or withdrawn for “insufficient information on botanical raw materials”, and late-phase trials met the hurdle of “the rigorous evidence-based requirements necessary for drug approval”. FDA's 2016 Botanical Drug Development guidance answers with a “totality of the evidence” approach to batch consistency.
| Product | Active ingredient | Application | Approved |
|---|---|---|---|
| Veregen | Sinecatechins | NDA | 2006 |
| Fulyzaq (also Mytesi) | Crofelemer | NDA | 2012 |
| NexoBrid | Anacaulase-bcdb | BLA | 2022 |
| Filsuvez | Birch triterpenes | NDA | 2023 |
Sources: FDA CDER, What is a Botanical Drug? (updated September 3, 2026); years from Park et al. 2025. None of the four is for an oncology indication.
Traditional use is exposure, not proof
Centuries of use show that people took a preparation and that acute, obvious harm was not noticed. They cannot show which species and dose were used, whether the effect beat placebo, or whether slow harms such as cancer or kidney failure occurred. Both histories below began in classical texts; one ended in a Nobel Prize, the other in an IARC Group 1 listing.
| Botanical | Finding | Lesson | Source |
|---|---|---|---|
| Qinghao (Artemisia annua) | A cold-water preparation in Ge Hong's text led to low-temperature extraction; sample 191 was 100% effective in rodent malaria on October 4, 1971; artemisinin was isolated in November 1972 | The text pointed to a method; isolation and trials made the medicine | Tu, Nobel Lecture 2015 |
| St John's wort (Hypericum perforatum) | 29 trials, 5,489 patients with major depression: extracts “superior to placebo, similarly effective as standard antidepressants, and had fewer side effects”; products “vary to a great extent” | An effect can be real and still not transfer from one product to another | Linde et al., Cochrane 2008, CD000448.pub3 |
| St John's wort, interaction | An extract supplying 41 mg hyperforin a day for 14 days cut oral midazolam exposure (AUC0–12 h) by 79.4% in one of six parallel groups of a 42-man study | Effective herbs can lower exposure to other medicines | Mueller et al., Eur J Clin Pharmacol 2006 |
| Aristolochia species | Substituted into Belgian slimming pills; 18 of 39 patients with end-stage nephropathy who had surgery had urothelial carcinoma | Identity errors and slow harms are invisible to tradition | Nortier et al., NEJM 2000; IARC Group 1 |
| Green tea catechins (EGCG) | 800 mg EGCG a day or more as a food supplement significantly raised serum transaminases; EFSA was “unable to identify a safe dose” | A concentrated extract is not the traditional infusion | EFSA ANS Panel, EFSA Journal 2018;16(4):5239 |
| Ephedra | FDA declared supplements containing ephedrine alkaloids adulterated as presenting an unreasonable risk (final rule February 11, 2004) | Traditional use did not predict harm at supplement doses | 69 FR 6788 |
| Herbal and dietary supplements, all | 130 of 839 drug-induced liver injury cases (15.5%) in the DILIN registry; share rose from 7% to 20% over the study | Caveat: a referral-center cohort; the authors did not conclude a national rise | Navarro et al., Hepatology 2014;60:1399–1408 |
All sources opened or confirmed October 28, 2026; full citations in the reference list.
Middle paths in other systems
Several systems license a traditional-use product for minor, self-care indications on bibliographic evidence of long use plus quality and safety data, without efficacy trials. None of the EU, Canadian or Australian routes extends to serious disease. The United States has no such middle tier: a botanical either carries a structure/function or health claim, or becomes a drug. WHO's Traditional Medicine Strategy 2025–2034 was adopted by the 78th World Health Assembly on May 27, 2025; WHO reports that 170 Member States report the use of traditional medicine.
| System | Route | Evidence of use | Claim scope | Source |
|---|---|---|---|---|
| European Union | Simplified registration of a traditional herbal medicinal product | Medicinal use for at least 30 years before application, including at least 15 years in the Community; data must show the product is not harmful and its effects plausible | Indications appropriate without medical supervision; oral, external or inhaled; fixed strength and posology; label says the use is “exclusively based upon long-standing use” | Directive 2004/24/EC, Arts 16a, 16c, 16g |
| Canada | Natural health product license (NPN) before sale; site license to make or import | “Two generations of safe traditional use”; one recognized system per formulation (TCM, Ayurveda, First Nations ethnomedicine, traditional herbal medicine) | Wording names the system (“traditionally used in Ayurvedic medicine”); serious-disease claims need modern evidence | Natural Health Products Regulations; Health Canada traditional-medicines pathway (modified July 6, 2022) |
| Australia | Listed medicine (AUST L) with permitted low-risk ingredients, made under GMP | Sponsor certifies it holds evidence; indications “not evaluated by the TGA at the time a medicine is listed” | Health maintenance and enhancement, and certain non-serious, self-limiting conditions | TGA, Listed complementary medicines (May 4, 2018) |
| China | Simplified registration of compound preparations from ancient classical prescriptions | Review combines TCM theory, human-use experience and clinical trials; classical-prescription preparations need no non-clinical efficacy research or clinical trials | Registered as medicines; scope not assessed here | TCM Law, adopted December 25, 2016, in force July 1, 2017; Special Regulations on TCM Registration, in force July 1, 2023, Arts 6, 13, 48 |
| India | Ayurvedic, Siddha and Unani drugs under the Drugs and Cosmetics Act, 1940; Ministry of Ayush | Made “exclusively in accordance with the formulae described in” authoritative books listed in the First Schedule | Defined as drugs for diagnosis, treatment, mitigation or prevention of disease; licensing detail not assessed here | CDSCO, Traditional Drugs page; Drugs and Cosmetics Rules, 1945, Part XVI |
| United States | None based on traditional use | Not a recognized basis for a claim | Structure/function or health claims; disease treatment only as an approved drug | 21 USC 321(g)(1), 343(r) |
Sources: EUR-Lex 32004L0024; Health Canada, Pathway for Licensing Natural Health Products used as Traditional Medicines; TGA; National Health Commission of China, December 26, 2016; NMPA Special Regulations (English text in NMPA newsletter, 2024); CDSCO; WHO document A78/14 and WHO news, November 14, 2025. Traditional use elsewhere does not by itself authorize sale in the EU or the United States.
What can legitimately be done
The gap cannot be closed by wording; it is closed by evidence on a defined product. The claim goal decides the route, and for a disease-treatment goal the order of events matters before any study is public. FDA's 2016 guidance gives one concrete advantage to traditional botanicals already sold lawfully: early clinical studies may need less chemistry detail and no new nonclinical testing when prior human use is similar to the proposed use.
| Remedy | What it gives | What it requires | EUTECNIQ would |
|---|---|---|---|
| Standardized, identified extract | A defined product that a trial result can attach to | Identity testing of every dietary ingredient (21 CFR 111.75(a)(1)(i)); marker and fingerprint specifications | Write specifications before any study starts |
| Registered, published trials on that product | Substantiation for structure/function statements; the evidence base for any later petition | Prospective registration, IRB review, the finished product as tested | Design and oversee trials run by qualified partners |
| Health claim or qualified health claim petition | A disease-risk-reduction claim usable by any product meeting the conditions | Significant scientific agreement, or for a qualified claim weaker evidence with qualifying language | Assess whether the evidence supports a petition |
| Botanical IND, often in a separate entity | A path to a treatment claim, plus statutory exclusivity on approval | 2016 guidance: raw-material, CMC and bioassay control across batches; adequate clinical evidence | Prepare the CMC and consistency package; sponsorship by a partner or spin-out |
| Early first-lawful-use decision | Keeps or deliberately closes the supplement channel | A decision before any drug investigation is public (21 USC 321(ff)(3)(B)) | Flag the decision at the first gate of each program, with counsel |
| Traditional-use license abroad | A labeled traditional indication in the EU, Canada or Australia | Each system's evidence rules, quality data and a local applicant | Compile bibliographic and quality dossiers for partners |
EUTECNIQ column: proposal only; no program, study, petition or IND exists. Route requirements as cited in the sections above.
Safe and consistent botanicals
Each failure listed under traditional use maps to a control that exists today. The methods are covered in depth on the linked pages; this table shows where each one enters.
| Failure mode | Control | Rule or method | Read more |
|---|---|---|---|
| Wrong species or adulterant | Identity test before use | 21 CFR 111.75(a)(1)(i); orthogonal methods, since a single method can mislead | Plant identity |
| Variable composition | Standardization and batch consistency | Marker and fingerprint specifications; for drugs, FDA's totality-of-evidence approach (2016) | Analytical technologies |
| Dose not known to be safe | Dose from a NOAEL and a human-equivalent dose | HED = animal dose × (animal weight ÷ human weight)0.33; for the rat, divide the mg/kg dose by 6.2 (FDA 2005, Table 1) | Risk assessment |
| Interactions with medicines | Clinical interaction studies on the product | Probe-substrate studies such as the St John's wort–midazolam study above | ADME and PBPK |
| Slow harms (cancer, kidney) | Repeated-dose and long-term toxicity studies | OECD test guidelines run under GLP (21 CFR Part 58) | Toxicology programs |
| Harm seen only after launch | Post-market adverse-event reporting | Serious adverse events reported to FDA within 15 business days (21 USC 379aa-1) | Lessons learned |
Sources: eCFR 21 CFR 111.75 and Part 58; FDA, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (July 2005), Table 1 and Table 3 footnote; 21 USC 379aa-1. The HED arithmetic is a teaching example, not a dosing method.
Where EUTECNIQ would work
EUTECNIQ would build the product-specific evidence the gap demands: identity and standardization first, then registered trials through partners, then a deliberate route decision for each ingredient, including when a drug program belongs in a separate entity. It would make no disease claims for supplements. Proposed
Related pages: Course 10, Supplements and disease claims · Proposed pipeline · Clinical research · International market access · NDIN strategy and dossiers · History of botanical medicine
Planning evidence for a traditional botanical?
Start with identity, a defined product and the route decision. EUTECNIQ is in formation and welcomes early conversations.
Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.
Read the full notice
The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.